Bioxcel therapeutics announces termination of proposed public offering

New haven, conn., feb. 13, 2024 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has terminated its proposed public offering of $60.0 million of shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, previously announced on february 8, 2024. as a result of such termination, no securities of the company are being sold pursuant to the offering.
BTAI Ratings Summary
BTAI Quant Ranking